The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113).
Chigusa Morizane
Honoraria - Lilly; Novartis; Pfizer
Takuji Okusaka
No relevant relationships to disclose
Junki Mizusawa
No relevant relationships to disclose
Hiroshi Katayama
No relevant relationships to disclose
Makoto Ueno
Honoraria - Abbott Japan
Masafumi Ikeda
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Hiroshi Ishii
No relevant relationships to disclose
Takeshi Azuma
No relevant relationships to disclose
Haruo Iguchi
No relevant relationships to disclose
Shoji Nakamori
No relevant relationships to disclose
Nobumasa Mizuno
No relevant relationships to disclose
Naohiro Sata
No relevant relationships to disclose
Kazuya Sugimori
No relevant relationships to disclose
Kensei Yamaguchi
No relevant relationships to disclose
Tetsuya Mine
No relevant relationships to disclose
Keiji Sano
No relevant relationships to disclose
Hiroyuki Maguchi
No relevant relationships to disclose
Kyoko Shimizu
No relevant relationships to disclose
Junji Furuse
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical